Lunai Bioworks (NASDAQ: LNAI) back in bid compliance but under 1-year Nasdaq monitor

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lunai Bioworks, Inc. has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), which calls for a bid price of at least $1.00 per share. Nasdaq confirmed that Lunai met the conditions set by a Nasdaq Hearings Panel in prior decision and extension letters.

The company will now be subject to a mandatory one-year monitoring period under Nasdaq Listing Rule 5815(d)(4)(B). If Lunai again falls out of compliance with the bid price rule during this period, Nasdaq staff would issue a delist determination without granting additional cure time, although Lunai could request a new hearing to stay any suspension or delisting while that process concludes.

Positive

Nasdaq bid-price compliance regained: Lunai Bioworks has restored compliance with Nasdaq Listing Rule 5550(a)(2), confirming its common stock again meets the $1.00-per-share minimum bid requirement and removing an immediate listing-compliance overhang.

Negative

Strict one-year monitoring period: For one year under Nasdaq Listing Rule 5815(d)(4)(B), any renewed bid-price deficiency would trigger an immediate delist determination without additional cure time, increasing operational risk around maintaining listing status.

Insights

Lunai regains Nasdaq bid-price compliance but faces strict one-year monitoring.

Lunai Bioworks has restored compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Meeting the prior Panel conditions removes an immediate delisting threat and helps preserve access to the Nasdaq Capital Market.

Under Nasdaq Listing Rule 5815(d)(4)(B), Lunai is now under a one-year mandatory Panel monitor. If it again violates the bid price rule in that timeframe, Nasdaq staff must issue a delist determination without offering an additional compliance plan or cure period.

Any such delist determination could still be appealed to a new Nasdaq Hearings Panel under Listing Rule 5815(d)(4)(C), which would stay suspension or delisting during the hearing process. The practical impact depends on Lunai’s ability to maintain its share price above the $1.00 threshold over the monitoring year.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Minimum bid price requirement: $1.00 per share Monitoring period length: one year

2 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) Bid Price Rule

Monitoring period length one year Mandatory Panel monitor under Nasdaq Listing Rule 5815(d)(4)(B)

Key Terms

Nasdaq Listing Rule 5550(a)(2), Bid Price Rule, Nasdaq Hearings Panel, delist determination letter

4 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities"

Bid Price Rule regulatory

"maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”)"

Nasdaq Hearings Panel regulatory

"terms set forth in the Nasdaq Hearings Panel’s decision and extension letters"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

delist determination letter regulatory

"the staff of Nasdaq would issue a delist determination letter, and the Company"

A delist determination letter is a formal notice from a stock exchange telling a company it no longer meets listing rules and is facing removal from the exchange. For investors, it signals that the stock may lose its regular trading venue, which can sharply reduce liquidity and visibility—like being forced out of a busy shopping mall into a small flea market—raising the risk of price drops and harder-to-sell shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/16/2026 - 04:00 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2026

LUNAI BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38758	45-2259340
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3400 Cottage Way, Suite G2, #3256

Sacramento, California 95825

(Address of principal executive offices) (Zip Code)

+1 (424) 222-9301

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	LNAI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 11, 2026, Lunai Bioworks, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Panel has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”), and that the Company has met the terms set forth in the Nasdaq Hearings Panel’s decision and extension letters dated April 20, 2026, and May 12, 2026, respectively.

Nasdaq also informed the Company that, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory Panel monitor for a period of one year from the date of Nasdaq’s letter. During the monitoring period, if the staff of Nasdaq determines that the Company is again out of compliance with the Bid Price Rule that was the subject of the exception, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to submit a plan of compliance with respect to that deficiency, the staff of Nasdaq will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, and the Company will not be afforded any otherwise applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). However, the staff of Nasdaq would issue a delist determination letter, and the Company would have the opportunity to request a new hearing before the Nasdaq Hearings Panel in accordance with Nasdaq Listing Rule 5815(d)(4)(C). The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LUNAI BIOWORKS, INC.

	By:
	Name:	David Weinstein
Date: June 16, 2026	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Lunai Bioworks (LNAI) announce regarding its Nasdaq listing?

Lunai Bioworks announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that Lunai met all conditions previously set by a Nasdaq Hearings Panel.

What is Nasdaq Listing Rule 5550(a)(2) and how does it affect LNAI?

Nasdaq Listing Rule 5550(a)(2) is the minimum bid price rule, requiring listed securities to maintain at least a $1.00 per share bid. Lunai Bioworks’ compliance with this rule helps preserve its Nasdaq Capital Market listing status.

Why is Lunai Bioworks under a one-year Nasdaq monitoring period?

Under Nasdaq Listing Rule 5815(d)(4)(B), Lunai Bioworks will be monitored for one year after regaining compliance. During this time, any renewed violation of the minimum bid price rule would prompt a delist determination without extra cure time.

What happens if LNAI falls below Nasdaq’s bid price requirement during monitoring?

If Lunai again breaches the minimum bid price rule during the one-year monitoring, Nasdaq staff must issue a delist determination. Lunai could then request a new hearing, which would stay any suspension or delisting while that hearing proceeds.

Does Lunai Bioworks get another cure period if it becomes non-compliant again?

During the one-year monitoring period, Lunai Bioworks would not receive another cure or compliance period for a new bid-price deficiency. Nasdaq staff cannot accept a new compliance plan or extend time, and must instead issue a delist determination.

Can Lunai Bioworks appeal a future Nasdaq delisting decision?

Yes. If Nasdaq issues a delist determination related to the bid price rule, Lunai Bioworks may request a new hearing under Nasdaq Listing Rule 5815(d)(4)(C). Filing this request would stay any suspension or delisting while the hearing process concludes.

Filing Exhibits & Attachments

3 documents